Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Purchases $20,250.00 in Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman purchased 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average cost of $4.05 per share, for a total transaction of $20,250.00. Following the acquisition, the chief executive officer owned 16,005 shares of the company’s stock, valued at approximately $64,820.25. This trade represents a 45.43% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Seth Lederman also recently made the following trade(s):

• On Thursday, August 27th, Seth Lederman acquired 2,000 shares of Tonix Pharmaceuticals stock. The stock was acquired at an average price of $13.79 per share, for a total transaction of $27,580.00.

Tonix Pharmaceuticals Stock Performance

NASDAQ:TNXP opened at $3.87 on Thursday. The firm has a market capitalization of $75.19 million, a price-to-earnings ratio of -0.32 and a beta of 1.90. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $3.82 and a 52-week high of $20.56. The stock has a fifty day moving average of $8.13 and a 200 day moving average of $12.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Monday, November 9th. The company reported ($2.89) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.50). The business had revenue of $17.23 million for the quarter, compared to analysts’ expectations of $16.32 million. Tonix Pharmaceuticals had a negative return on equity of 78.17% and a negative net margin of 420.45%. Equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -9.90 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TNXP. Raymond James Financial reissued a “strong-buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, October 20th. Canaccord Genuity Group initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday, October 26th. They issued a “buy” rating and a $18.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. Finally, Wall Street Zen raised shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, October 4th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $22.33.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its holdings in shares of Tonix Pharmaceuticals by 101.1% in the 1st quarter. Bank of America Corp DE now owns 60,958 shares of the company’s stock worth $838,000 after purchasing an additional 30,644 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Tonix Pharmaceuticals during the 2nd quarter valued at about $533,000. Great Lakes Advisors LLC purchased a new position in shares of Tonix Pharmaceuticals during the 2nd quarter valued at about $303,000. Integrated Wealth Concepts LLC bought a new stake in Tonix Pharmaceuticals in the 2nd quarter worth approximately $92,000. Finally, Global Retirement Partners LLC bought a new stake in Tonix Pharmaceuticals in the 3rd quarter worth approximately $28,000. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving the central nervous system, immunology and infectious diseases. The company’s research programs are designed to address disorders with significant unmet medical needs, including chronic pain, neuropsychiatric conditions and infectious diseases. Tonix’s pipeline has included TNX-102 SL, an investigational sublingual formulation of cyclobenzaprine being studied for fibromyalgia and other pain-related conditions.